Advertisement

Drugs

, Volume 58, Supplement 2, pp 222–224 | Cite as

Single Dose Pharmacokinetics of the R- and S-Enantiomers of Gatifloxacin in Volunteers

  • H.-J. Stahlberg
  • K. Goehler
  • M. Guillaume
  • A. Mignot
Poster Presentations Extended Abstract

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hirai K, Yasue T, Hosaka M, et al. In vitro antibacterial activity of AM-1155. Drugs 1993; 45 Suppl. 3: 182–3CrossRefGoogle Scholar
  2. 2.
    Hosaka M, Yasue T, Fukuda H, et al. In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother 1992; 36: 2108–17PubMedCrossRefGoogle Scholar
  3. 3.
    Toraioka H, Saito H, Sato K. Comparative antimycobacterial activities of the newly synthesised quinolone AM-1155, sparfloxacin and ofloxacin. Antimicrob Agents Chemother 1993; 37: 1259–63CrossRefGoogle Scholar
  4. 4.
    Wakabayashi E, Mitsuhashi S. In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother 1994; 38: 594–601PubMedCrossRefGoogle Scholar
  5. 5.
    Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 12-8093, gatifloxacin (AM 1155) trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother 1997; 40: 639–51PubMedCrossRefGoogle Scholar
  6. 6.
    Nakashima M, Uematsu T, Kosuge K, et al. Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrob Agents Chemother 1995; 39: 2635–40PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  • H.-J. Stahlberg
    • 1
  • K. Goehler
    • 1
  • M. Guillaume
    • 2
  • A. Mignot
    • 2
  1. 1.Grünenthal GmbH, Clinical Research AntiinfectivesAachenGermany
  2. 2.Aster/CephacParisFrance

Personalised recommendations